Concurrent purification approach could cut ADC manufacture by 25%, ADC Bio

By Dan Stanton contact

- Last updated on GMT

GettyImages/EtiAmmos
GettyImages/EtiAmmos

Related tags: Monoclonal antibodies, Manufacturing

ADC Bio has developed a concurrent conjugation and antibody purification process, not reliant on Protein A capture resin.

The Wales, UK-based contract manufacturing organisation (CMO) is yet to have given the process a name but says it undertakes bioconjugation for antibody-drug conjugates (ADCs) after both the monoclonal antibody (mAb) and cytotoxic have been manufactured, with purification of both carried out simultaneously.

According to ADC Biotechnolgy CEO Charlie Johnson, this represents a manufacturing paradigm by integrating several downstream methods and thus reducing the number of CMOs involved in the supply chain.

He added this will “save several months of manufacturing time and up to 25% of the overall costs.”

Mimicking Protein A

But another cost-saving factor is this approach uses ADC Bio’s ‘Lock-Release’ technology​, which does not rely on Protein A capture resin, Johnson told this publication.

Protein A is deemed the gold standard for monoclonal antibody capture​, but with a price tag as high as $12,000 per litre, it can account for a large percentage of the total bioproduction cost.

“ADC Bio does not use Protein A – instead, we use mimetic resins which mimic Protein A resins,” ​Johnson said.

“These mimetic resins have the benefit of being cheaper to make than Protein A and also have the distinct advantage of not leaching Protein A. Leaching is a significant industry problem with Protein A usage.”

He estimated that by not using Protein A, mAb makers can make savings of between 25% and 30%.

“Not only are you saving money by removing the need for the Protein A step, but also time and costs in the downstream processing.”

Related news

Show more

Related products

show more

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Related suppliers

Follow us

Products

View more

Webinars